Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Biosciences to Review Strategic Alternatives

NEW YORK — Interpace Biosciences said on Thursday that it will undertake a strategic review of its business as it works to increase shareholder value following its recent delisting from the Nasdaq.

In February, Interpace announced that it had received a delisting notice from the Nasdaq for its failure to meet the exchange's minimum $2.5 million stockholders' equity requirement. At the time, the Parsippany, New Jersey-based company — which now trades on the Over-The-Counter Markets — also said that it was reorganizing in order to save $7.2 million in annual costs.

In April, Interpace reported that it was on track to meet this cost-cutting goal and that its revenues for the fourth quarter had more than doubled. On Thursday, the company said that it has raised its 2021 revenue guidance to between $42 million and $44 million from previous guidance of $38 million to $40 million.

Despite the expected revenue growth, Interpace said that its board believes its current stock price does not reflect the company's overall value. As a result, it is working with adviser Guggenheim Securities on a "review of a broad range of alternatives to enhance shareholder value."

During early morning trading, shares of Interpace were up $.60 to $8.50.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.